金融界8月26日消息，据CDE官网沟通交流公示，于8月26日收到瑞石生物医药有限公司申请的“III类会议”，当前状态“处理中”。
根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议，就关键阶段重大问题进行沟通交流，Ⅲ类会议一般安排在申请后75日内召开。
瑞石生物医药有限公司，成立于2018年，位于上海市，是一家以从事研究和试验发展为主的企业。企业注册资本10000万美元。
通过天眼查大数据分析，瑞石生物医药有限公司知识产权方面有商标信息12条，专利信息37条，此外企业还拥有行政许可8个。
主要股东信息显示，瑞石生物医药有限公司由Reistone Biopharma (Hong Kong) Limited持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.